Currently, there are a limited number of CAR T-cell clinical trials for children with CNS tumors, all at phase I. Targets include HER2, B7 homolog 3 (B7H3), EGFR806, the disialoganglioside GD2 and IL13Rα2 (Table 1). Here, CD276 is linked to central nervous system neoplasm.